NCT01046487 2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1 Completed
Clinical Trials
188 trialsNCT03939026 2026-03-02
ALPHA
Allogene Therapeutics
Phase 1 Completed
NCT04052334 2026-02-20
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT05987696 2026-02-11
Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Completed
NCT04674813 2026-02-09
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene
Phase 1 Completed
NCT05694364 2026-02-06
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT06464965 2026-01-26
Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer
Zhejiang Provincial People's Hospital
Phase 1 Completed
NCT01175356 2026-01-23
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Children's Oncology Group
Phase 1 Completed
NCT05182073 2025-12-12
FT576 in Subjects With Multiple Myeloma
Fate Therapeutics
Phase 1 Completed
NCT02950259 2025-12-03
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
Providence Health & Services
Phase 1 Completed
NCT02996773 2025-11-10
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
Phase 1 Completed
NCT02512926 2025-10-15
POE14-01
Stanford University
Phase 1 Completed
NCT03107988 2025-09-15
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT02650648 2025-07-30
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02775292 2025-07-30
NYM
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT01385423 2025-07-24
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT04473911 2025-07-20
Haplo Peripheral Blood Sct In GVHD Prevention
Massachusetts General Hospital
Phase 1 Completed
NCT02446964 2025-06-22
Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia
City of Hope Medical Center
Phase 1 Completed
NCT04088890 2025-06-10
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Stanford University
Phase 1 Completed
NCT02517918 2025-06-08
METZOLIMOS
Institut Bergonié
Phase 1 Completed
NCT02303821 2025-06-04
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Amgen
Phase 1 Completed
NCT03448393 2025-06-04
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02905188 2025-02-24
GLYCAR
Baylor College of Medicine
Phase 1 Completed
NCT02030964 2025-02-17
DFMO
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT03475134 2025-02-11
TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
Centre Hospitalier Universitaire Vaudois
Phase 1 Completed
NCT04023669 2025-02-07
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02876510 2025-02-04
ACTolog
Immatics US, Inc.
Phase 1 Completed
NCT03467373 2025-01-17
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
Hoffmann-La Roche
Phase 1 Completed
NCT03092453 2024-12-24
Dendritic Cell Vaccination in Patients With Advanced Melanoma
University of Pennsylvania
Phase 1 Completed
NCT04319757 2024-12-05
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Acepodia Biotech, Inc.
Phase 1 Completed
NCT02926053 2024-11-22
TIL Therapy for Metastatic Renal Cell Carcinoma
Herlev Hospital
Phase 1 Completed
NCT00719173 2024-11-04
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT04714372 2024-10-24
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT04187898 2024-09-19
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Spectrum Pharmaceuticals, Inc
Phase 1 Completed
NCT01606241 2024-08-21
Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 1 Completed
NCT01798004 2024-07-15
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Children's Oncology Group
Phase 1 Completed
NCT02107963 2024-05-16
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03728179 2024-02-20
RACIN
Centre Hospitalier Universitaire Vaudois
Phase 1 Completed
NCT02513186 2024-01-29
Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation
Sanofi
Phase 1 Completed
NCT01606878 2024-01-05
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT03919526 2023-12-08
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 1 Completed
NCT00562640 2023-09-15
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT04081389 2023-09-11
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT03338972 2023-09-08
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT04196491 2023-08-23
KarMMa-4
Celgene
Phase 1 Completed
NCT01614197 2023-07-27
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT03215810 2023-07-24
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03328104 2023-07-21
ENCERT
Emory University
Phase 1 Completed
NCT03991884 2023-07-06
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
University of Washington
Phase 1 Completed
NCT00003927 2023-07-05
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
City of Hope Medical Center
Phase 1 Completed